Kitea Health is pioneering a proactive strategy for managing hydrocephalus using cutting-edge micro-implantable devices that continuously monitor internal pressure in the brain.

Imagine a future where you and your clinician can manage your healthur health needs effectively, from the comfort of your own home, while avoiding the costs and stresses of frequent hospital visits. Kitea’s micro-implants represent a chance to leverage medical technology to deliver cheaper, more precise, and timely care for patients.

Founded by Simon Malpas, Bryon Wright and Natalia Lopez and based in Auckland, Kitea Health emerged from the Auckland Bioengineering Institute and is an existing portfolio company of Enterprise Angels. The company garnered significant early support from the Health Research Council, Ministry of Business Innovation and Employment, and various charitable organizations. Kitea now also has the backing of multiple, well regarded institutional investors including Icehouse Ventures, NZGCP and Australian Medtech investor Bioshore Partners.

Currently, they’re in the clinical stage of developing their first device, aimed at tackling hydrocephalus—a condition marked by excessive fluid in the brain. They have completed safety trial in adults, implanting children and gearing up for FDA approval to conduct a pivotal trial in the US.

 With their innovative approach and strong backing, Kitea Health looking to revolutionise how we manage chronic conditions, bringing us closer to a future where proactive care is the norm. 

Read more here.